Margarida Maia, PhD, science writer —

Margarida is a biochemist (University of Porto, Portugal) with a PhD in biomedical sciences (VIB and KULeuven, Belgium). Her main interest is science communication. She is also passionate about design and the dialogue between art and science.

Articles by Margarida Maia

Plasma Exchange Plus IVIG May Ease MG Symptoms, Boost Immunity

Plasma exchange combined with intravenous, or into-the-vein, immunoglobulin (IVIG) appears to be safe, and better than plasma therapy alone at easing the symptoms of myasthenia gravis (MG) and boosting the immunity of patients, a study suggests. These findings offer what researchers called a “reference for clinical decision-making” — particularly…

MG at Advanced Stage Follows Thymus Surgery in Older Man

A man developed myasthenia gravis (MG), which quickly progressed to an advanced stage, shortly after surgery to remove a tumor in the thymus gland, according to a report from China. Post-surgical MG is rare and its rapid severity even rarer, its scientists noted, and this man’s  MG diagnosis was more…

#AAN2022 – Long-term Vyvgart Eases gMG Symptoms

Long-term treatment with Vyvgart (efgartigimod alfa-fcab) is safe and well tolerated, and leads to a sustained improvement in generalized myasthenia gravis (gMG) disease scores. These findings come from an interim analysis of ADAPT+ (NCT03770403), an ongoing Phase 3, open-label, three-year extension of ADAPT (NCT03669588) that is…

Rozanolixizumab May Safely Ease Symptom Severity in gMG Patients

Rozanolixizumab, UCB’s investigational antibody, may ease symptom severity in adults with generalized myasthenia gravis (MG), and help them carry on with daily activities, top-line data from the Phase 3 MycarinG study suggests. Moreover, rozanolixizumab, given as an under-the-skin (subcutaneous) infusion, was found to be generally safe and…